Abemaciclib

Active ingredient description

Abemaciclib is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), and most active against Cyclin D1/CDK4 in enzymatic assays. Abemaciclib prevents retinoblastoma protein (Rb) phosphorylation, blocking cell cycle progression from the G1 to the S-phase of cell division, leading to suppression of tumour growth.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
L01EF03
Abemaciclib
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EF Cyclin-dependent kinase (CDK) inhibitors
Discover more medicines within L01EF03

Medicines

Abemaciclib is the active ingredient of these drugs:

Drug
Countries
VERZENIO

Australia Canada Hong Kong Singapore United States

VERZENIOS

Austria Brazil Cyprus France Ireland

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
VERZENIOS Film-coated tablet
Summary of product characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

60UAB198HK - ABEMACICLIB

SNOMED-CT

761851004 - Abemaciclib (substance)

Next: Usage